Content area

|
|

Antifosfolipidsyndrom og graviditet

Forfatter(e)
Karen Schreiber1, 2, Jacob Alexander Lykke3, Jens Langhoff-Roos3, Henriette Svarre Nielsen4 & Søren Jacobsen1 1) Klinik for Højt Specialiseret Reumatologi, Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet 2) Centre for Thrombosis, St Thomas‘ Hospital, London, England 3) Obstetrisk Klinik Y, Rigshospitalet 4) Fertilitetsklinikken, Rigshospitalet Ugeskr Læger 2016;178;V09150730
Reference: 
Ugeskr Læger 2016;178:V09150730
Blad nummer: 
Sidetal: 
2-5
Antiphospholipid syndrome and pregnancy
Antiphospholipid syndrome (APS) is the association of antiphospholipid antibodies with thromboses and/or obstetric morbidity. Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, pre-eclam­psia, premature birth and fetal growth restriction. Although current treatment regimens including aspirin and low-molecular weight heparin have improved pregnancy out­comes, 30% of affected women have pregnancy complica­tions. Women with APS are therefore high-risk pregnancies who should be monitored in specialist centres according to international standards.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Pedram Kazemi-Esfarjani | 28/11
2 kommentarer
af David McWhan | 27/11
4 kommentarer
af Ulf Bern Jensen | 24/11
2 kommentarer
af Bodil Marie Nielsen | 24/11
2 kommentarer
af Jan Nielsen | 23/11
1 Kommentar
af Toke Seierøe Barfod | 23/11
2 kommentarer
af Thorkild I.A. Sørensen | 20/11
1 Kommentar
af Kim Varming | 20/11
1 Kommentar
af Niels Holmark Andersen | 20/11
1 Kommentar